Esophageal Diseases  >>  TheraCIM (nimotuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
NCT02011594: Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma

Withdrawn
2
0
RoW
Nimotuzumab, Anti epidermal growth factor receptor antibody h-R3, Placebo, Normal saline
Zhejiang University
Stage IV Esophageal Squamous Cell Carcinoma
01/15
02/15
NCT02034968: Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma

Withdrawn
2
0
RoW
Nimotuzumab, Anti epidermal growth factor receptor antibody h-R3
Zhejiang University
Stage IV Esophageal Squamous Cell Carcinoma
01/16
01/17
NCT02041819: Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus

Withdrawn
2
0
RoW
Nimotuzumab, nimo
Zhejiang University
Squamous Cell Carcinoma of Esophagus
01/16
01/17

Download Options